ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
타이사브리(나탈리주맙) 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 266만 달러에서 2026년에는 287만 달러에 이르고, CAGR 8.1%로 성장할 전망입니다. 지난 수년간의 성장에는 다발성 경화증 유병률 증가, 나탈리주맙 치료제의 승인, 신경과 전문의들의 채용 확대, 진행성 다발성 경화증에 대한 미충족 수요, 정맥주사 센터의 확대 등이 주요 요인으로 꼽힙니다.
타이사브리(나탈리주맙) 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 387만 달러에 이르고, CAGR은 7.8%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 다발성 경화증 진단율 향상, 수액 인프라 개선, 위험 완화 프로그램 강화, 전문 신경과 서비스 확대, 장기적인 임상 결과 지원 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 다발성 경화증에 대한 단일클론항체 사용 확대, 고효능 질환 조절 요법 선호, 외래 정맥주사 치료 확대, 안전성 및 위험성 모니터링 프로토콜 개선, 진행성 다발성 경화증 관리에 대한 관심 증가 등이 있습니다.
자가면역질환의 유병률 증가는 향후 몇 년간 타이사브리(나탈리주맙) 시장의 성장을 견인할 것으로 예측됩니다. 자가면역질환은 면역체계가 자신의 세포, 조직, 장기를 잘못 공격하여 염증과 손상을 일으키는 질환입니다. 이러한 상태는 유전적 요인과 환경적 요인이 복합적으로 관여하여 류마티스 관절염, 다발성 경화증과 같은 만성질환으로 이어질 수 있습니다. 자가면역질환 증가는 유전적 소인, 환경적 요인, 그리고 인식과 진단의 향상으로 인한 환자 수 증가에 기인합니다. 타이사브리는 특정 면역세포를 표적으로 하여 염증과 조직 손상을 유발하는 것을 방지하여 다발성 경화증, 크론병 등의 질병 관리에 효과적입니다. 예를 들어, 2024년 2월, 관절염 및 근골격계 질환을 앓고 있는 사람들을 지원하는 자선단체인 Arthritis Australia는 2025년까지 약 56만 2,378명의 호주인이 류마티스 관절염(RA)을 앓고 있을 것이라고 보고했습니다. 이는 전체 관절염 환자의 14%에 해당합니다. 그 결과, 자가면역질환의 유병률 증가가 타이사브리(나탈리주맙) 시장의 성장을 가속하고 있습니다.
개인 맞춤형 의료에 대한 관심이 높아지는 것도 타이사브리(나탈리주맙) 시장의 성장을 가속할 것으로 예측됩니다. 맞춤형 의료는 환자 개개인의 유전적 특성, 환경, 생활습관 등 개인별 특성에 맞게 치료법과 헬스케어 전략을 조정하여 보다 효과적이고 정밀한 치료 결과를 달성하는 것입니다. 맞춤의료의 부상은 유전체 기술의 발전, 분자생물학에 대한 이해의 심화, 정밀 진단 도구의 보급 확대, 그리고 부작용을 줄이면서 환자 결과를 개선하는 표적치료에 대한 수요에 의해 촉진되고 있습니다. 타이사브리는 특정 질병 활성도 및 위험 프로파일을 가진 환자를 대상으로 재발성 다발성 경화증에 대한 표적 치료 접근법을 제공함으로써 효능을 극대화하고 잠재적 부작용을 최소화함으로써 맞춤형 의료의 좋은 본보기가 되고 있습니다. 예를 들어, 2024년 2월 미국 비영리단체 '맞춤의료연합'이 발표한 보고서에 따르면, 2023년 FDA가 승인한 희귀질환에 대한 신규 맞춤치료제는 16건(2022년 6건)에 달하며, 이 중 암 치료용이 7건, 기타 질환 및 증상용이 3건을 차지합니다. 따라서 맞춤형 의료의 발전이 타이사브리(나탈리주맙) 시장의 성장을 견인하고 있다고 할 수 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 시장 규제 상황과 투자환경
제29장 경쟁 구도와 기업 개요
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 시장 잠재력이 높은 국가, 부문, 전략
제33장 부록
LSH
영문 목차
영문목차
Tysabri (natalizumab) is a monoclonal antibody used to treat relapsing multiple sclerosis (MS) and Crohn's disease by reducing inflammation and protecting nerves from damage. It helps decrease the frequency of relapses and slows the progression of physical disability in adults with relapsing forms of MS, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).
The primary indications for Tysabri (natalizumab) are multiple sclerosis and Crohn's disease. Multiple sclerosis is a condition that causes the deterioration of the protective covering of nerves. Tysabri is used in various patient settings, including inpatient and outpatient care, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have influenced the tysabri market by increasing costs for monoclonal antibody production inputs, infusion supplies, and cold chain transportation. These cost pressures are most evident in hospital and outpatient infusion centers. North america and europe experience reimbursement sensitivity due to reliance on imported biologics. However, tariffs are encouraging regional biologic manufacturing investments. This is strengthening long-term supply stability and patient access.
The tysabri (natalizumab) market research report is one of a series of new reports from The Business Research Company that provides tysabri (natalizumab) market statistics, including tysabri (natalizumab) industry global market size, regional shares, competitors with a tysabri (natalizumab) market share, detailed tysabri (natalizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the tysabri (natalizumab) industry. This tysabri (natalizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tysabri (natalizumab) market size has grown strongly in recent years. It will grow from $2.66 million in 2025 to $2.87 million in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing multiple sclerosis prevalence, approval of natalizumab therapy, neurologist adoption, unmet need in aggressive ms, infusion center expansion.
The tysabri (natalizumab) market size is expected to see strong growth in the next few years. It will grow to $3.87 million in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growth in ms diagnosis rates, improved infusion infrastructure, enhanced risk mitigation programs, rising specialty neurology services, long-term clinical outcome support. Major trends in the forecast period include growing use of monoclonal antibodies in ms, preference for high efficacy disease modifying therapies, expansion of outpatient infusion care, improved safety and risk monitoring protocols, rising focus on progressive ms management.
The increasing prevalence of autoimmune disorders is expected to drive the growth of the Tysabri (natalizumab) market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's own cells, tissues, or organs, causing inflammation and damage. These conditions can lead to chronic illnesses such as rheumatoid arthritis or multiple sclerosis, with causes involving a combination of genetic and environmental factors. The rise in autoimmune disorders is attributed to genetic predisposition, environmental triggers, and improved awareness and diagnosis, resulting in more cases being identified. Tysabri is effective for autoimmune disorders as it targets specific immune cells, preventing them from causing inflammation and tissue damage, helping manage conditions like multiple sclerosis and Crohn's disease. For example, in February 2024, Arthritis Australia, a charitable organization advocating for people with arthritis and musculoskeletal conditions, reported that by 2025, around 562,378 Australians are expected to live with rheumatoid arthritis (RA), representing 14% of the total arthritis population. Consequently, the rising prevalence of autoimmune disorders is fueling growth in the Tysabri (natalizumab) market.
The growing focus on personalized medicine is also expected to propel the Tysabri (natalizumab) market forward. Personalized medicine tailors treatments and healthcare strategies to the individual characteristics of each patient, including their genetic profile, environment, and lifestyle, to achieve more effective and precise outcomes. The rise of personalized medicine is driven by advancements in genomic technologies, greater understanding of molecular biology, wider availability of precision diagnostic tools, and demand for targeted therapies that improve patient outcomes while reducing side effects. Tysabri exemplifies personalized medicine by providing a targeted treatment approach for relapsing forms of multiple sclerosis, specifically for patients with certain disease activity and risk profiles, maximizing efficacy while minimizing potential adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022, including seven drugs tailored for cancer and three for other diseases and conditions. Therefore, the rise of personalized medicine is driving growth in the Tysabri (natalizumab) market.
Key players in the Tysabri (natalizumab) market are focusing on expanding treatment options with alternatives such as biosimilars to provide patients with more effective therapies that enhance quality of life and disease management. Biosimilars to Tysabri offer a cost-effective option for treating highly active relapsing-remitting multiple sclerosis, improving access to essential treatments, especially in underserved areas. For instance, in January 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, launched Tyruko (natalizumab), the first and only biosimilar to Tysabri, for adults with highly active relapsing-remitting multiple sclerosis (RRMS). This launch strengthens Sandoz's biosimilar portfolio and aims to increase access to effective and affordable treatments for people living with multiple sclerosis.
Major companies operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, Polpharma Biologics
North America was the largest region in the tysabri (natalizumab) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tysabri (natalizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the tysabri (natalizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
The tysabri market consists of sales of monoclonal antibody therapies, infusion treatments, and immunomodulatory solutions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tysabri (natalizumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses tysabri (natalizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for tysabri (natalizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tysabri (natalizumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Clinical Indication: Multiple Sclerosis; Crohn's Disease
2) By Patient Setting: Inpatient; Outpatient
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: Biogen Idec Inc.; Sandoz International GmbH; Polpharma Biologics
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.2 Preference For High Efficacy Disease Modifying Therapies
4.2.3 Expansion Of Outpatient Infusion Care
4.2.4 Improved Safety And Risk Monitoring Protocols
4.2.5 Rising Focus On Progressive Ms Management
5. Tysabri (natalizumab) Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Neurology Clinics
5.3 Infusion Centers
5.4 Specialty Pharmacies
5.5 Multiple Sclerosis Centers
6. Tysabri (natalizumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Tysabri (natalizumab) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Tysabri (natalizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Tysabri (natalizumab) Market Size, Comparisons And Growth Rate Analysis
7.3. Global Tysabri (natalizumab) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Tysabri (natalizumab) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Tysabri (natalizumab) Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Tysabri (natalizumab) Market Segmentation
9.1. Global Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Multiple Sclerosis, Crohn's Disease
9.2. Global Tysabri (natalizumab) Market, Segmentation By Patient Setting, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Inpatient, Outpatient
9.3. Global Tysabri (natalizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Tysabri (natalizumab) Market
12.1. China Tysabri (natalizumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Tysabri (natalizumab) Market
13.1. India Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Tysabri (natalizumab) Market
14.1. Japan Tysabri (natalizumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Tysabri (natalizumab) Market
15.1. Australia Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. South Korea Tysabri (natalizumab) Market
16.1. South Korea Tysabri (natalizumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
16.2. South Korea Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. Western Europe Tysabri (natalizumab) Market
17.1. Western Europe Tysabri (natalizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. Western Europe Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. UK Tysabri (natalizumab) Market
18.1. UK Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. Germany Tysabri (natalizumab) Market
19.1. Germany Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. France Tysabri (natalizumab) Market
20.1. France Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. Eastern Europe Tysabri (natalizumab) Market
21.1. Eastern Europe Tysabri (natalizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
21.2. Eastern Europe Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. North America Tysabri (natalizumab) Market
22.1. North America Tysabri (natalizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
22.2. North America Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. USA Tysabri (natalizumab) Market
23.1. USA Tysabri (natalizumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
23.2. USA Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
24.2. Canada Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. South America Tysabri (natalizumab) Market
25.1. South America Tysabri (natalizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
25.2. South America Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Middle East Tysabri (natalizumab) Market
26.1. Middle East Tysabri (natalizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Middle East Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Africa Tysabri (natalizumab) Market
27.1. Africa Tysabri (natalizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
27.2. Africa Tysabri (natalizumab) Market, Segmentation By Clinical Indication, Segmentation By Patient Setting, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. Tysabri (natalizumab) Market Regulatory and Investment Landscape
29. Tysabri (natalizumab) Market Competitive Landscape And Company Profiles
29.1. Tysabri (natalizumab) Market Competitive Landscape And Market Share 2024
29.1.1. Top 10 Companies (Ranked by revenue/share)
29.2. Tysabri (natalizumab) Market - Company Scoring Matrix
29.2.1. Market Revenues
29.2.2. Product Innovation Score
29.2.3. Brand Recognition
29.3. Tysabri (natalizumab) Market Company Profiles
29.3.1. Biogen Idec Inc. Overview, Products and Services, Strategy and Financial Analysis
29.3.2. Sandoz International GmbH Overview, Products and Services, Strategy and Financial Analysis
29.3.3. Polpharma Biologics Overview, Products and Services, Strategy and Financial Analysis
30. Global Tysabri (natalizumab) Market Competitive Benchmarking And Dashboard
31. Key Mergers And Acquisitions In The Tysabri (natalizumab) Market
32. Tysabri (natalizumab) Market High Potential Countries, Segments and Strategies
32.1 Tysabri (natalizumab) Market In 2030 - Countries Offering Most New Opportunities
32.2 Tysabri (natalizumab) Market In 2030 - Segments Offering Most New Opportunities
32.3 Tysabri (natalizumab) Market In 2030 - Growth Strategies
32.3.1 Market Trend Based Strategies
32.3.2 Competitor Strategies
33. Appendix
33.1. Abbreviations
33.2. Currencies
33.3. Historic And Forecast Inflation Rates
33.4. Research Inquiries
33.5. The Business Research Company
33.6. Copyright And Disclaimer
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
